Global Trivalent Flu Vaccine Market

Trivalent Flu Vaccine Comprehensive Study by Application (Hospital, Clinic, Public Health Agency, Other), Distribution Channel (Pharmacies, Grocery Stores, Health Food Shops, Internet Sales, Mail Order, Direct Marketing Routes), Dosage Form (Intramuscular Injection, Nasal Spray, Intradermal Shot) Players and Region - Global Market Outlook to 2027

Trivalent Flu Vaccine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Trivalent Flu Vaccine
The companies operated in this industry are exploring the market in various new regions by adopting strategic initiatives including join ventures, enhancement, investments, new product launches and partnerships as their strategies. Leading players are enhancing the market in new areas with the help of the expansions and acquisitions across the globe to avail competitive benefits through combined synergies.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The global trivalent flu vaccine market is moderately competitive and having of some leading players. In concern of the vendor’s share, some of the leading players are highly dominating the global market. These market players are focusing on strategic collaborative initiatives to enhance their market share and improve their profitability. Analyst at AMA Research estimates that Asia Pacific Players will contribute the maximum growth to Global Trivalent Flu Vaccine market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Abbott (United States), AstraZeneca (United Kingdom), BioCryst Pharmaceuticals, Inc. (United States), Novartis AG (United States), Daiichi Sankyo Company, Ltd. (Japan), GlaxoSmithKline plc. (United Kingdom), Hualan Biological Engineering Inc. (China), Mitsubishi Tanabe Pharma Corporation (Japan), F. Hoffmann-La Roche Ltd (Switzerland) and Novavax (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Seqirus Vaccines Limited (United Kingdom) and FluGen (United States).

Segmentation Overview
AMA Research has segmented the market of Global Trivalent Flu Vaccine market by , Application (Hospital, Clinic, Public Health Agency and Other) and Region.



On the basis of geography, the market of Trivalent Flu Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Pharmacies will boost the Trivalent Flu Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dosage Form, the sub-segment i.e. Intramuscular Injection will boost the Trivalent Flu Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In 2021, Pfizer has begun research on an mRNA-based next-generation flu vaccine. Pfizer worked with a German biotechnology company called BioNTech to develop a new mRNA technology for generating flu vaccine shots. The manufacturing process for this RNA vaccine will be simpler and will create a new vaccine within eight days after a new flu virus is known. Pfizer's mRNA vaccine program was the first planned program to include mRNA technology for influenza., In 2020, Abbott has launched a new inactivated quadrivalent vaccine against influenza., Sanofi invested more than Euro 600 million in a new vaccine plant in Toronto in April 2021 to increase the supply of influenza vaccines in Canada, the United States and Europe. and CSL announced the launch of the AUDENZ vaccine, which can be used to protect against the H5N1 influenza A virus in February 2020.


Market Drivers
  • Growing Focus on Preventing Healthcare

Opportunities
  • Increasing Number of Manufacturers

Restraints
  • High Cost of Raw Materials

Challenges
  • Lack of Consumers’ Awareness


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Trivalent Flu Vaccine Manufacturers, Suppliers and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Application
  • Hospital
  • Clinic
  • Public Health Agency
  • Other
By Distribution Channel
  • Pharmacies
  • Grocery Stores
  • Health Food Shops
  • Internet Sales
  • Mail Order
  • Direct Marketing Routes

By Dosage Form
  • Intramuscular Injection
  • Nasal Spray
  • Intradermal Shot

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Focus on Preventing Healthcare
    • 3.3. Market Challenges
      • 3.3.1. Lack of Consumers’ Awareness
    • 3.4. Market Trends
      • 3.4.1. Rising Online Purchasing Behaviour of Consumers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Trivalent Flu Vaccine, by Application, Distribution Channel, Dosage Form and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Trivalent Flu Vaccine (Value)
      • 5.2.1. Global Trivalent Flu Vaccine by: Application (Value)
        • 5.2.1.1. Hospital
        • 5.2.1.2. Clinic
        • 5.2.1.3. Public Health Agency
        • 5.2.1.4. Other
      • 5.2.2. Global Trivalent Flu Vaccine by: Distribution Channel (Value)
        • 5.2.2.1. Pharmacies
        • 5.2.2.2. Grocery Stores
        • 5.2.2.3. Health Food Shops
        • 5.2.2.4. Internet Sales
        • 5.2.2.5. Mail Order
        • 5.2.2.6. Direct Marketing Routes
      • 5.2.3. Global Trivalent Flu Vaccine by: Dosage Form (Value)
        • 5.2.3.1. Intramuscular Injection
        • 5.2.3.2. Nasal Spray
        • 5.2.3.3. Intradermal Shot
      • 5.2.4. Global Trivalent Flu Vaccine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Trivalent Flu Vaccine (Volume)
      • 5.3.1. Global Trivalent Flu Vaccine by: Application (Volume)
        • 5.3.1.1. Hospital
        • 5.3.1.2. Clinic
        • 5.3.1.3. Public Health Agency
        • 5.3.1.4. Other
      • 5.3.2. Global Trivalent Flu Vaccine by: Distribution Channel (Volume)
        • 5.3.2.1. Pharmacies
        • 5.3.2.2. Grocery Stores
        • 5.3.2.3. Health Food Shops
        • 5.3.2.4. Internet Sales
        • 5.3.2.5. Mail Order
        • 5.3.2.6. Direct Marketing Routes
      • 5.3.3. Global Trivalent Flu Vaccine by: Dosage Form (Volume)
        • 5.3.3.1. Intramuscular Injection
        • 5.3.3.2. Nasal Spray
        • 5.3.3.3. Intradermal Shot
      • 5.3.4. Global Trivalent Flu Vaccine Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Trivalent Flu Vaccine (Price)
  • 6. Trivalent Flu Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BioCryst Pharmaceuticals, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Daiichi Sankyo Company, Ltd. (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hualan Biological Engineering Inc. (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mitsubishi Tanabe Pharma Corporation (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novavax (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Trivalent Flu Vaccine Sale, by Application, Distribution Channel, Dosage Form and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Trivalent Flu Vaccine (Value)
      • 7.2.1. Global Trivalent Flu Vaccine by: Application (Value)
        • 7.2.1.1. Hospital
        • 7.2.1.2. Clinic
        • 7.2.1.3. Public Health Agency
        • 7.2.1.4. Other
      • 7.2.2. Global Trivalent Flu Vaccine by: Distribution Channel (Value)
        • 7.2.2.1. Pharmacies
        • 7.2.2.2. Grocery Stores
        • 7.2.2.3. Health Food Shops
        • 7.2.2.4. Internet Sales
        • 7.2.2.5. Mail Order
        • 7.2.2.6. Direct Marketing Routes
      • 7.2.3. Global Trivalent Flu Vaccine by: Dosage Form (Value)
        • 7.2.3.1. Intramuscular Injection
        • 7.2.3.2. Nasal Spray
        • 7.2.3.3. Intradermal Shot
      • 7.2.4. Global Trivalent Flu Vaccine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Trivalent Flu Vaccine (Volume)
      • 7.3.1. Global Trivalent Flu Vaccine by: Application (Volume)
        • 7.3.1.1. Hospital
        • 7.3.1.2. Clinic
        • 7.3.1.3. Public Health Agency
        • 7.3.1.4. Other
      • 7.3.2. Global Trivalent Flu Vaccine by: Distribution Channel (Volume)
        • 7.3.2.1. Pharmacies
        • 7.3.2.2. Grocery Stores
        • 7.3.2.3. Health Food Shops
        • 7.3.2.4. Internet Sales
        • 7.3.2.5. Mail Order
        • 7.3.2.6. Direct Marketing Routes
      • 7.3.3. Global Trivalent Flu Vaccine by: Dosage Form (Volume)
        • 7.3.3.1. Intramuscular Injection
        • 7.3.3.2. Nasal Spray
        • 7.3.3.3. Intradermal Shot
      • 7.3.4. Global Trivalent Flu Vaccine Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Trivalent Flu Vaccine (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Trivalent Flu Vaccine: by Application(USD Million)
  • Table 2. Trivalent Flu Vaccine Hospital , by Region USD Million (2016-2021)
  • Table 3. Trivalent Flu Vaccine Clinic , by Region USD Million (2016-2021)
  • Table 4. Trivalent Flu Vaccine Public Health Agency , by Region USD Million (2016-2021)
  • Table 5. Trivalent Flu Vaccine Other , by Region USD Million (2016-2021)
  • Table 6. Trivalent Flu Vaccine: by Distribution Channel(USD Million)
  • Table 7. Trivalent Flu Vaccine Pharmacies , by Region USD Million (2016-2021)
  • Table 8. Trivalent Flu Vaccine Grocery Stores , by Region USD Million (2016-2021)
  • Table 9. Trivalent Flu Vaccine Health Food Shops , by Region USD Million (2016-2021)
  • Table 10. Trivalent Flu Vaccine Internet Sales , by Region USD Million (2016-2021)
  • Table 11. Trivalent Flu Vaccine Mail Order , by Region USD Million (2016-2021)
  • Table 12. Trivalent Flu Vaccine Direct Marketing Routes , by Region USD Million (2016-2021)
  • Table 13. Trivalent Flu Vaccine: by Dosage Form(USD Million)
  • Table 14. Trivalent Flu Vaccine Intramuscular Injection , by Region USD Million (2016-2021)
  • Table 15. Trivalent Flu Vaccine Nasal Spray , by Region USD Million (2016-2021)
  • Table 16. Trivalent Flu Vaccine Intradermal Shot , by Region USD Million (2016-2021)
  • Table 17. South America Trivalent Flu Vaccine, by Country USD Million (2016-2021)
  • Table 18. South America Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 19. South America Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 20. South America Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 21. Brazil Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 22. Brazil Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 23. Brazil Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 24. Argentina Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 25. Argentina Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 26. Argentina Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 27. Rest of South America Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 28. Rest of South America Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 29. Rest of South America Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 30. Asia Pacific Trivalent Flu Vaccine, by Country USD Million (2016-2021)
  • Table 31. Asia Pacific Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 32. Asia Pacific Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 33. Asia Pacific Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 34. China Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 35. China Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 36. China Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 37. Japan Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 38. Japan Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 39. Japan Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 40. India Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 41. India Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 42. India Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 43. South Korea Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 44. South Korea Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 45. South Korea Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 46. Taiwan Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 47. Taiwan Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 48. Taiwan Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 49. Australia Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 50. Australia Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 51. Australia Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 52. Rest of Asia-Pacific Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 53. Rest of Asia-Pacific Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 54. Rest of Asia-Pacific Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 55. Europe Trivalent Flu Vaccine, by Country USD Million (2016-2021)
  • Table 56. Europe Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 57. Europe Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 58. Europe Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 59. Germany Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 60. Germany Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 61. Germany Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 62. France Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 63. France Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 64. France Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 65. Italy Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 66. Italy Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 67. Italy Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 68. United Kingdom Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 69. United Kingdom Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 70. United Kingdom Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 71. Netherlands Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 72. Netherlands Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 73. Netherlands Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 74. Rest of Europe Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 75. Rest of Europe Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 76. Rest of Europe Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 77. MEA Trivalent Flu Vaccine, by Country USD Million (2016-2021)
  • Table 78. MEA Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 79. MEA Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 80. MEA Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 81. Middle East Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 82. Middle East Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 83. Middle East Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 84. Africa Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 85. Africa Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 86. Africa Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 87. North America Trivalent Flu Vaccine, by Country USD Million (2016-2021)
  • Table 88. North America Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 89. North America Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 90. North America Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 91. United States Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 92. United States Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 93. United States Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 94. Canada Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 95. Canada Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 96. Canada Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 97. Mexico Trivalent Flu Vaccine, by Application USD Million (2016-2021)
  • Table 98. Mexico Trivalent Flu Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 99. Mexico Trivalent Flu Vaccine, by Dosage Form USD Million (2016-2021)
  • Table 100. Trivalent Flu Vaccine Sales: by Application(K Units)
  • Table 101. Trivalent Flu Vaccine Sales Hospital , by Region K Units (2016-2021)
  • Table 102. Trivalent Flu Vaccine Sales Clinic , by Region K Units (2016-2021)
  • Table 103. Trivalent Flu Vaccine Sales Public Health Agency , by Region K Units (2016-2021)
  • Table 104. Trivalent Flu Vaccine Sales Other , by Region K Units (2016-2021)
  • Table 105. Trivalent Flu Vaccine Sales: by Distribution Channel(K Units)
  • Table 106. Trivalent Flu Vaccine Sales Pharmacies , by Region K Units (2016-2021)
  • Table 107. Trivalent Flu Vaccine Sales Grocery Stores , by Region K Units (2016-2021)
  • Table 108. Trivalent Flu Vaccine Sales Health Food Shops , by Region K Units (2016-2021)
  • Table 109. Trivalent Flu Vaccine Sales Internet Sales , by Region K Units (2016-2021)
  • Table 110. Trivalent Flu Vaccine Sales Mail Order , by Region K Units (2016-2021)
  • Table 111. Trivalent Flu Vaccine Sales Direct Marketing Routes , by Region K Units (2016-2021)
  • Table 112. Trivalent Flu Vaccine Sales: by Dosage Form(K Units)
  • Table 113. Trivalent Flu Vaccine Sales Intramuscular Injection , by Region K Units (2016-2021)
  • Table 114. Trivalent Flu Vaccine Sales Nasal Spray , by Region K Units (2016-2021)
  • Table 115. Trivalent Flu Vaccine Sales Intradermal Shot , by Region K Units (2016-2021)
  • Table 116. South America Trivalent Flu Vaccine Sales, by Country K Units (2016-2021)
  • Table 117. South America Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 118. South America Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 119. South America Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 120. Brazil Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 121. Brazil Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 122. Brazil Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 123. Argentina Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 124. Argentina Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 125. Argentina Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 126. Rest of South America Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 127. Rest of South America Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 128. Rest of South America Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 129. Asia Pacific Trivalent Flu Vaccine Sales, by Country K Units (2016-2021)
  • Table 130. Asia Pacific Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 131. Asia Pacific Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 132. Asia Pacific Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 133. China Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 134. China Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 135. China Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 136. Japan Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 137. Japan Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 138. Japan Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 139. India Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 140. India Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 141. India Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 142. South Korea Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 143. South Korea Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 144. South Korea Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 145. Taiwan Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 146. Taiwan Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 147. Taiwan Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 148. Australia Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 149. Australia Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 150. Australia Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 151. Rest of Asia-Pacific Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 152. Rest of Asia-Pacific Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 153. Rest of Asia-Pacific Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 154. Europe Trivalent Flu Vaccine Sales, by Country K Units (2016-2021)
  • Table 155. Europe Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 156. Europe Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 157. Europe Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 158. Germany Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 159. Germany Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 160. Germany Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 161. France Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 162. France Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 163. France Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 164. Italy Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 165. Italy Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 166. Italy Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 167. United Kingdom Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 168. United Kingdom Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 169. United Kingdom Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 170. Netherlands Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 171. Netherlands Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 172. Netherlands Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 173. Rest of Europe Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 174. Rest of Europe Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 175. Rest of Europe Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 176. MEA Trivalent Flu Vaccine Sales, by Country K Units (2016-2021)
  • Table 177. MEA Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 178. MEA Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 179. MEA Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 180. Middle East Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 181. Middle East Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 182. Middle East Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 183. Africa Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 184. Africa Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 185. Africa Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 186. North America Trivalent Flu Vaccine Sales, by Country K Units (2016-2021)
  • Table 187. North America Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 188. North America Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 189. North America Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 190. United States Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 191. United States Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 192. United States Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 193. Canada Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 194. Canada Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 195. Canada Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 196. Mexico Trivalent Flu Vaccine Sales, by Application K Units (2016-2021)
  • Table 197. Mexico Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2016-2021)
  • Table 198. Mexico Trivalent Flu Vaccine Sales, by Dosage Form K Units (2016-2021)
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Trivalent Flu Vaccine: by Application(USD Million)
  • Table 210. Trivalent Flu Vaccine Hospital , by Region USD Million (2022-2027)
  • Table 211. Trivalent Flu Vaccine Clinic , by Region USD Million (2022-2027)
  • Table 212. Trivalent Flu Vaccine Public Health Agency , by Region USD Million (2022-2027)
  • Table 213. Trivalent Flu Vaccine Other , by Region USD Million (2022-2027)
  • Table 214. Trivalent Flu Vaccine: by Distribution Channel(USD Million)
  • Table 215. Trivalent Flu Vaccine Pharmacies , by Region USD Million (2022-2027)
  • Table 216. Trivalent Flu Vaccine Grocery Stores , by Region USD Million (2022-2027)
  • Table 217. Trivalent Flu Vaccine Health Food Shops , by Region USD Million (2022-2027)
  • Table 218. Trivalent Flu Vaccine Internet Sales , by Region USD Million (2022-2027)
  • Table 219. Trivalent Flu Vaccine Mail Order , by Region USD Million (2022-2027)
  • Table 220. Trivalent Flu Vaccine Direct Marketing Routes , by Region USD Million (2022-2027)
  • Table 221. Trivalent Flu Vaccine: by Dosage Form(USD Million)
  • Table 222. Trivalent Flu Vaccine Intramuscular Injection , by Region USD Million (2022-2027)
  • Table 223. Trivalent Flu Vaccine Nasal Spray , by Region USD Million (2022-2027)
  • Table 224. Trivalent Flu Vaccine Intradermal Shot , by Region USD Million (2022-2027)
  • Table 225. South America Trivalent Flu Vaccine, by Country USD Million (2022-2027)
  • Table 226. South America Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 227. South America Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 228. South America Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 229. Brazil Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 230. Brazil Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 231. Brazil Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 232. Argentina Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 233. Argentina Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 234. Argentina Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 235. Rest of South America Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 236. Rest of South America Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 237. Rest of South America Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 238. Asia Pacific Trivalent Flu Vaccine, by Country USD Million (2022-2027)
  • Table 239. Asia Pacific Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 240. Asia Pacific Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 241. Asia Pacific Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 242. China Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 243. China Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 244. China Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 245. Japan Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 246. Japan Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 247. Japan Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 248. India Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 249. India Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 250. India Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 251. South Korea Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 252. South Korea Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 253. South Korea Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 254. Taiwan Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 255. Taiwan Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 256. Taiwan Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 257. Australia Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 258. Australia Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 259. Australia Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 260. Rest of Asia-Pacific Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 261. Rest of Asia-Pacific Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 262. Rest of Asia-Pacific Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 263. Europe Trivalent Flu Vaccine, by Country USD Million (2022-2027)
  • Table 264. Europe Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 265. Europe Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 266. Europe Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 267. Germany Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 268. Germany Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 269. Germany Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 270. France Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 271. France Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 272. France Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 273. Italy Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 274. Italy Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 275. Italy Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 276. United Kingdom Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 277. United Kingdom Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 278. United Kingdom Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 279. Netherlands Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 280. Netherlands Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 281. Netherlands Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 282. Rest of Europe Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 283. Rest of Europe Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 284. Rest of Europe Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 285. MEA Trivalent Flu Vaccine, by Country USD Million (2022-2027)
  • Table 286. MEA Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 287. MEA Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 288. MEA Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 289. Middle East Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 290. Middle East Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 291. Middle East Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 292. Africa Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 293. Africa Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 294. Africa Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 295. North America Trivalent Flu Vaccine, by Country USD Million (2022-2027)
  • Table 296. North America Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 297. North America Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 298. North America Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 299. United States Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 300. United States Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 301. United States Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 302. Canada Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 303. Canada Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 304. Canada Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 305. Mexico Trivalent Flu Vaccine, by Application USD Million (2022-2027)
  • Table 306. Mexico Trivalent Flu Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 307. Mexico Trivalent Flu Vaccine, by Dosage Form USD Million (2022-2027)
  • Table 308. Trivalent Flu Vaccine Sales: by Application(K Units)
  • Table 309. Trivalent Flu Vaccine Sales Hospital , by Region K Units (2022-2027)
  • Table 310. Trivalent Flu Vaccine Sales Clinic , by Region K Units (2022-2027)
  • Table 311. Trivalent Flu Vaccine Sales Public Health Agency , by Region K Units (2022-2027)
  • Table 312. Trivalent Flu Vaccine Sales Other , by Region K Units (2022-2027)
  • Table 313. Trivalent Flu Vaccine Sales: by Distribution Channel(K Units)
  • Table 314. Trivalent Flu Vaccine Sales Pharmacies , by Region K Units (2022-2027)
  • Table 315. Trivalent Flu Vaccine Sales Grocery Stores , by Region K Units (2022-2027)
  • Table 316. Trivalent Flu Vaccine Sales Health Food Shops , by Region K Units (2022-2027)
  • Table 317. Trivalent Flu Vaccine Sales Internet Sales , by Region K Units (2022-2027)
  • Table 318. Trivalent Flu Vaccine Sales Mail Order , by Region K Units (2022-2027)
  • Table 319. Trivalent Flu Vaccine Sales Direct Marketing Routes , by Region K Units (2022-2027)
  • Table 320. Trivalent Flu Vaccine Sales: by Dosage Form(K Units)
  • Table 321. Trivalent Flu Vaccine Sales Intramuscular Injection , by Region K Units (2022-2027)
  • Table 322. Trivalent Flu Vaccine Sales Nasal Spray , by Region K Units (2022-2027)
  • Table 323. Trivalent Flu Vaccine Sales Intradermal Shot , by Region K Units (2022-2027)
  • Table 324. South America Trivalent Flu Vaccine Sales, by Country K Units (2022-2027)
  • Table 325. South America Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 326. South America Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 327. South America Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 328. Brazil Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 329. Brazil Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 330. Brazil Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 331. Argentina Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 332. Argentina Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 333. Argentina Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 334. Rest of South America Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 335. Rest of South America Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 336. Rest of South America Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 337. Asia Pacific Trivalent Flu Vaccine Sales, by Country K Units (2022-2027)
  • Table 338. Asia Pacific Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 339. Asia Pacific Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 340. Asia Pacific Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 341. China Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 342. China Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 343. China Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 344. Japan Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 345. Japan Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 346. Japan Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 347. India Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 348. India Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 349. India Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 350. South Korea Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 351. South Korea Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 352. South Korea Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 353. Taiwan Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 354. Taiwan Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 355. Taiwan Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 356. Australia Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 357. Australia Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 358. Australia Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 359. Rest of Asia-Pacific Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 360. Rest of Asia-Pacific Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 361. Rest of Asia-Pacific Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 362. Europe Trivalent Flu Vaccine Sales, by Country K Units (2022-2027)
  • Table 363. Europe Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 364. Europe Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 365. Europe Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 366. Germany Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 367. Germany Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 368. Germany Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 369. France Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 370. France Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 371. France Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 372. Italy Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 373. Italy Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 374. Italy Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 375. United Kingdom Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 376. United Kingdom Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 377. United Kingdom Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 378. Netherlands Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 379. Netherlands Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 380. Netherlands Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 381. Rest of Europe Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 382. Rest of Europe Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 383. Rest of Europe Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 384. MEA Trivalent Flu Vaccine Sales, by Country K Units (2022-2027)
  • Table 385. MEA Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 386. MEA Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 387. MEA Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 388. Middle East Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 389. Middle East Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 390. Middle East Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 391. Africa Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 392. Africa Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 393. Africa Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 394. North America Trivalent Flu Vaccine Sales, by Country K Units (2022-2027)
  • Table 395. North America Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 396. North America Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 397. North America Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 398. United States Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 399. United States Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 400. United States Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 401. Canada Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 402. Canada Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 403. Canada Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 404. Mexico Trivalent Flu Vaccine Sales, by Application K Units (2022-2027)
  • Table 405. Mexico Trivalent Flu Vaccine Sales, by Distribution Channel K Units (2022-2027)
  • Table 406. Mexico Trivalent Flu Vaccine Sales, by Dosage Form K Units (2022-2027)
  • Table 407. Research Programs/Design for This Report
  • Table 408. Key Data Information from Secondary Sources
  • Table 409. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Trivalent Flu Vaccine: by Application USD Million (2016-2021)
  • Figure 5. Global Trivalent Flu Vaccine: by Distribution Channel USD Million (2016-2021)
  • Figure 6. Global Trivalent Flu Vaccine: by Dosage Form USD Million (2016-2021)
  • Figure 7. South America Trivalent Flu Vaccine Share (%), by Country
  • Figure 8. Asia Pacific Trivalent Flu Vaccine Share (%), by Country
  • Figure 9. Europe Trivalent Flu Vaccine Share (%), by Country
  • Figure 10. MEA Trivalent Flu Vaccine Share (%), by Country
  • Figure 11. North America Trivalent Flu Vaccine Share (%), by Country
  • Figure 12. Global Trivalent Flu Vaccine: by Application K Units (2016-2021)
  • Figure 13. Global Trivalent Flu Vaccine: by Distribution Channel K Units (2016-2021)
  • Figure 14. Global Trivalent Flu Vaccine: by Dosage Form K Units (2016-2021)
  • Figure 15. South America Trivalent Flu Vaccine Share (%), by Country
  • Figure 16. Asia Pacific Trivalent Flu Vaccine Share (%), by Country
  • Figure 17. Europe Trivalent Flu Vaccine Share (%), by Country
  • Figure 18. MEA Trivalent Flu Vaccine Share (%), by Country
  • Figure 19. North America Trivalent Flu Vaccine Share (%), by Country
  • Figure 20. Global Trivalent Flu Vaccine share by Players 2021 (%)
  • Figure 21. Global Trivalent Flu Vaccine share by Players (Top 3) 2021(%)
  • Figure 22. Global Trivalent Flu Vaccine share by Players (Top 5) 2021(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 25. Abbott (United States) Revenue: by Geography 2021
  • Figure 26. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. AstraZeneca (United Kingdom) Revenue: by Geography 2021
  • Figure 28. BioCryst Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. BioCryst Pharmaceuticals, Inc. (United States) Revenue: by Geography 2021
  • Figure 30. Novartis AG (United States) Revenue, Net Income and Gross profit
  • Figure 31. Novartis AG (United States) Revenue: by Geography 2021
  • Figure 32. Daiichi Sankyo Company, Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Daiichi Sankyo Company, Ltd. (Japan) Revenue: by Geography 2021
  • Figure 34. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2021
  • Figure 36. Hualan Biological Engineering Inc. (China) Revenue, Net Income and Gross profit
  • Figure 37. Hualan Biological Engineering Inc. (China) Revenue: by Geography 2021
  • Figure 38. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 39. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue: by Geography 2021
  • Figure 40. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 41. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2021
  • Figure 42. Novavax (United States) Revenue, Net Income and Gross profit
  • Figure 43. Novavax (United States) Revenue: by Geography 2021
  • Figure 44. Global Trivalent Flu Vaccine: by Application USD Million (2022-2027)
  • Figure 45. Global Trivalent Flu Vaccine: by Distribution Channel USD Million (2022-2027)
  • Figure 46. Global Trivalent Flu Vaccine: by Dosage Form USD Million (2022-2027)
  • Figure 47. South America Trivalent Flu Vaccine Share (%), by Country
  • Figure 48. Asia Pacific Trivalent Flu Vaccine Share (%), by Country
  • Figure 49. Europe Trivalent Flu Vaccine Share (%), by Country
  • Figure 50. MEA Trivalent Flu Vaccine Share (%), by Country
  • Figure 51. North America Trivalent Flu Vaccine Share (%), by Country
  • Figure 52. Global Trivalent Flu Vaccine: by Application K Units (2022-2027)
  • Figure 53. Global Trivalent Flu Vaccine: by Distribution Channel K Units (2022-2027)
  • Figure 54. Global Trivalent Flu Vaccine: by Dosage Form K Units (2022-2027)
  • Figure 55. South America Trivalent Flu Vaccine Share (%), by Country
  • Figure 56. Asia Pacific Trivalent Flu Vaccine Share (%), by Country
  • Figure 57. Europe Trivalent Flu Vaccine Share (%), by Country
  • Figure 58. MEA Trivalent Flu Vaccine Share (%), by Country
  • Figure 59. North America Trivalent Flu Vaccine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott (United States)
  • AstraZeneca (United Kingdom)
  • BioCryst Pharmaceuticals, Inc. (United States)
  • Novartis AG (United States)
  • Daiichi Sankyo Company, Ltd. (Japan)
  • GlaxoSmithKline plc. (United Kingdom)
  • Hualan Biological Engineering Inc. (China)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Novavax (United States)
Additional players considered in the study are as follows:
Seqirus Vaccines Limited (United Kingdom) , FluGen (United States)
Select User Access Type

Key Highlights of Report


Jul 2022 159 Pages 92 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Trivalent Flu Vaccine Market Quantitative research analysis
Global Trivalent Flu Vaccine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Abbott (United States), AstraZeneca (United Kingdom), BioCryst Pharmaceuticals, Inc. (United States), Novartis AG (United States), Daiichi Sankyo Company, Ltd. (Japan), GlaxoSmithKline plc. (United Kingdom), Hualan Biological Engineering Inc. (China), Mitsubishi Tanabe Pharma Corporation (Japan), F. Hoffmann-La Roche Ltd (Switzerland) and Novavax (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising Online Purchasing Behaviour of Consumers" is seen as one of major influencing trends for Trivalent Flu Vaccine Market during projected period 2021-2027.
The Trivalent Flu Vaccine market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Trivalent Flu Vaccine Market Report?

Have a Query? Click Here

Other Related Reports

Pediatric Antibiotics Comprehensive Study by Type (Amoxicillin, Amoxicillin Clavulanate, Clindamycin HCl, Cephalexin, Penicillin V Potassium), Application (Adults, Geriatric, Children (Greater Than 7...
$ 3750
Intranasal Corticosteroids Comprehensive Study by Type (Prescribed Drugs, OTC Drugs), Application (Hospital Pharmacies, Online Pharnacies, Retail Pharmacies), Indication (Perennial Allergic Rhinitis ...
$ 3750
Lovastatin Comprehensive Study by Product Form (Tablet, Extended-Release Tablets), Diseases (Chest Pain, Heart Attack, Stroke, Others), Distribution Channel (Pharmacies, Grocery Stores, Health Food ...
$ 3450
Antibacterial Masks Comprehensive Study by Type (Antibacterial Filter, Activated Carbon, Chitosan, Nano Silver, Filter Cloth), Application (Fire, Medical, Food Processing, Other), Antimicrobial Treat...
$ 3650
Acupuncture Needle Comprehensive Study by Type (Disposable Needle, Non-disposable Needle), Application (Hospitals, Clinics, Others), Distribution Channel (Online Stores, Medical Stores, Supermarket,...
$ 3750
Cannulated Fusion Screw Comprehensive Study by Application (Foot, Ankle), Surgery (Open Surgery, Minimally Invasive Surgery), End Use (Hospital, Clinic), End User (Adult, Children) Players and Region...
$ 3500